EYLEA HAS AN INNOVATIVE MOLECULAR DESIGN AND MECHANISM OF ACTION

^1–5

Prescribing information for EYLEA® (aflibercept) 2 mg

Fc, fragment crystallisable. IgG1, immunoglobulin G1. K_D, dissociation constant. nAMD, neovascular age-related macular degeneration. PIGF, placental growth factor. pM, picomolar. VEGF, vascular endothelial growth factor. VEGFR, vascular endothelial growth factor receptor.

EYLEA 2 mg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO), and visual impairment due to myopic choroidal neovascularisation (myopic CNV).¹

1. EYLEA® 40 mg/mL Summary of Product Characteristics.
2. Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
3. Kanda A, et al. Sci Rep 2015;5:17946.
4. Amadio M, et al. Pharmacol Res 2016;103:253–269.
5. Fauser S & Muether PS. Br J Ophthalmol 2016;100:1494–1498.
6. EMA. EYLEA EPAR assessment report 2012. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/eylea. Accessed: August 2024.
7. Holash J, et al. Proc Natl Acad Sci USA 2002;99:11393–11398.